Demand for medical testing services is rising.

DGX raised its 2026 outlook as testing demand surged, but lower-margin deals and rising project costs could temper the payoff ...

Quest Diagnostics (NYSE:DGX) reported double-digit revenue growth and raised its full-year 2026 outlook after what executives ...

In the last three months, 7 analysts have published ratings on Quest Diagnostics (NYSE:DGX), offering a diverse range of perspectives from bullish to bearish. In the table below, you'll find a summary ...

Quest Diagnostics shows Q2 earnings beat, upgraded FY guidance, and continued market momentum. Check out why DGX stock is a ...

Quest Diagnostics president and CEO Jim Davis discusses how his company is implementing AI to help its patients on 'The ...

Quest Diagnostics is launching a chatbot tailored for laboratory test results as it seeks to allow patients the ability to get a handle on their findings and perform deeper dives on their own health.

"We now expect revenues to be between $11.95 billion and $12.05 billion... Reported EPS to be in a range of $9.97 to $10.17 and adjusted EPS in a range of $11.05 to $11.25." (Executive VP & CFO Samad) ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell ...

Quest Diagnostics raised its full-year outlook after profit and sales rose in the second quarter. The diagnostic testing company on Thursday posted a profit of $320 million, or $2.84 a share, in the ...

Partnerships with other healthcare leaders are accelerating Quest's growth. AI is making the health insights provider more profitable. Shares of Quest Diagnostics (NYSE: DGX) rose more than 8% last ...